- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Luis E. Aguirre
Hematologic Oncology, Leukemia & Lymphoma
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Hematology (Internal Medicine), Internal Medicine
, and Medical Oncology
Titles
- Assistant Professor of Medicine (Medical Oncology & Hematology)
Education & Training
- MPHHarvard T.H. Chan School of Public Health (2026)
- Foley Family Fellowship in LeukemiaDana-Farber Cancer Institute, Harvard Medical School (2025)
- Non Degree ProgramHarvard Medical School, Program in Clinical Effectiveness (2023)
- Medical OncologyH. Lee Moffitt Cancer Center and Research Institute (2023)
- HematologyH. Lee Moffitt Cancer Center and Research Institute (2023)
- Internal MedicineUniversity of Miami Miller School of Medicine (2020)
Languages Spoken
- English
- Deutsch (German)
- Español (Spanish)
Additional Information
Honors & Recognitions
- ASCO Conquer Cancer Merit Award: American Society of Clinical Oncology (2025)
- ASH Abstract Merit Award: American Society of Hematology (2024)
- New Investigator Travel Award: AA & MDS International Foundation (2024)
- ASCO Conquer Cancer Merit Award: American Society of Clinical Oncology (2023)
- ASH Clinical Research Training Institute: American Society of Hematology (2023)
- Foley Family Fellowship in Leukemia: Dana-Farber Cancer Institute, Harvard Medical School (2023), (2024)
- EHA Young Investigator Merit Award: European Hematology Association (2023)
- Featured Presenter, Moffitt Cancer Center 13th Annual Scientific Symposium: Moffitt Cancer Center (2023)
- Hematology/Oncology Fellow Liaison to the Florida Society of Clinical Oncology Board of Directors: Florida Society of Clinical Oncology (2023)
- ASH Abstract Merit Award: American Society of Hematology (2022)
Board Certifications
- AB of Internal Medicine, Hematology (Internal Medicine) (2023)
- AB of Internal Medicine, Medical Oncology (2023)
- AB of Internal Medicine, Internal Medicine (2020)
Professional Service
- American Society of Hematology (2024 - Present): Abstract Reviewer
- Harvard Ecuadorian Student Association (2024 - Present): Member
- Florida Society of Clinical Oncology (2023 - 2024): Liaison
- Massachusetts Society of Clinical Oncologists (2023 - Present): Member
- European Hematology Association (2022 - Present): Member
- European Society for Medical Oncology (2021 - 2023): Member
- Society of Hematologic Oncology (2021 - Present): Member
- American Association for Cancer Research (AACR) (2021 - Present): Member
- American Medical Association (2018 - 2023): Member
- American Society of Clinical Oncology (2018 - Present): Member
Publications
- Aguirre L, Al Ali N, Ball S, Jain A, Sallman D, Kuykendall A, Walker A, Sweet K, Lancet J, Padron E, Komrokji R. A comparative assessment of molecular-based prognostic models in CMML. Blood Neoplasia 2025, 2: 100116. DOI: 10.1016/j.bneo.2025.100116.
- Ball S, Jain A, Al Ali N, Aguirre L, Bewersdorf J, Kent A, Rose A, Hayden A, Siddon A, Lykon J, Madarang E, Swoboda D, Padron E, Sweet K, Sallman D, Lancet J, Carraway H, Watts J, Zeidan A, Pollyea D, Komrokji R. Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia. American Journal Of Hematology 2025, 100: 1920-1923. PMID: 40772639, DOI: 10.1002/ajh.70031.
- Aguirre L, Kim H, Elmariah H, Frumm S, Kelkar A, Ho V, Gooptu M, Antin J, Soiffer R, Shimony S, Luskin M, Garcia J, Chen E, Winer E, Stone R, DeAngelo D, Al Ali N, Cutler C, Komrokji R, Stahl M. Impact of static and dynamic risk assessment in HMA-treated MDS patients undergoing stem cell transplantation. Journal Of Clinical Oncology 2025, 43: 6568-6568. DOI: 10.1200/jco.2025.43.16_suppl.6568.
- Aguirre L, Ball S, Jain A, Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression. Clinical Lymphoma Myeloma & Leukemia 2025, 25: 661-671. PMID: 40254502, DOI: 10.1016/j.clml.2025.03.016.
- Consagra A, Lanino L, Al Ali N, Aguirre L, Xie Z, Chan O, Andreossi G, Raddi M, Rigodanza L, Sanna A, Mattiuz G, Tofacchi E, Amato C, Tanturli M, De Pourcq S, Walker A, Kuykendall A, Lancet J, Padron E, Sallman D, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Maggioni G, Campagna A, Della Porta M, Santini V, Komrokji R. Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS. HemaSphere 2025, 9: e70086. PMID: 39944234, PMCID: PMC11814532, DOI: 10.1002/hem3.70086.
- Ball S, Al Ali N, Jain A, Aguirre L, Yun S, Chan O, Xie Z, Sallman D, Lancet J, Padron E, Komrokji R, Kuykendall A. Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia. Frontiers In Hematology 2024, 3: 1492680. DOI: 10.3389/frhem.2024.1492680.
- Iat A, Bewersdorf J, Gilhodes J, Liu Y, Shallis R, Boussi L, Zucenka A, Bystrom R, DeAngelo D, Berton G, Soua A, Ling K, Aguirre L, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Goldberg A, Zeidan A, Cluzeau T, Shimony S, Stahl M, Garciaz S. Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia. Blood 2024, 144: 1508. DOI: 10.1182/blood-2024-207045.
- Bystrom R, Bewersdorf J, Liu Y, Schaefer E, Shallis R, Boussi L, Zucenka A, Garciaz S, Aguirre L, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study. Blood 2024, 144: 2947-2947. DOI: 10.1182/blood-2024-205581.
- Boussi L, Bewersdorf J, Liu Y, Shallis R, Aguirre L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Zeidan A, Goldberg A, Stein E, Shimony S, Stahl M. Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities. Blood 2024, 144: 4281-4281. DOI: 10.1182/blood-2024-204467.
- Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics. Blood 2024, 144: 4267-4267. DOI: 10.1182/blood-2024-202744.
- Zhang J, Shimony S, Liu Y, Inyang E, Chen E, Aguirre L, Bystrom R, Rolles B, Stone R, DeAngelo D, Tiao E, Stahl M. Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy. Blood 2024, 144: 5175-5175. DOI: 10.1182/blood-2024-200358.
- Aguirre L, Jain A, Ball S, Ali N, Volpe V, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clinical Lymphoma Myeloma & Leukemia 2024, 24: 459-467. PMID: 38548563, DOI: 10.1016/j.clml.2024.03.001.
- Jain A, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica 2024, 109: 2157-2164. PMID: 38299605, PMCID: PMC11215361, DOI: 10.3324/haematol.2023.283661.
- Consagra A, Lanino L, Al Ali N, Aguirre L, Xie Z, Chan O, Andreossi G, Rigodanza L, Sanna A, Raddi M, Walker A, Kuykendall A, Lancet J, Padron E, Sallman D, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Campagna A, Della Porta M, Santini V, Komrokji R. Improved Overall Survival Among Luspatercept Responders and Predictors of Response. Blood 2023, 142: 1871. DOI: 10.1182/blood-2023-186279.
- Chan O, Aguirre L, Burke M, Al Ali N, Xie Z, Yun S, Kuykendall A, Padron E, Walker A, Lancet J, Komrokji R, Sallman D. Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax. Blood 2023, 142: 5935. DOI: 10.1182/blood-2023-173637.
- Patel P, Ball S, Jain A, Wang C, Hussaini M, Aguirre L, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet J, Komrokji R, Sallman D. Drivers of deep molecular response and long‐term outcomes in patients with core binding factor acute myeloid leukemia. American Journal Of Hematology 2023, 98: e360-e363. PMID: 37705256, DOI: 10.1002/ajh.27092.
- Aguirre L, Al Ali N, Sallman D, Kuykendall A, Chan O, Sweet K, Lancet J, Padron E, Komrokji R. MDS-266 A Comprehensive Assessment of the Molecular International Prognostic Scoring System (IPSS-M) and Other Molecularly Integrated Risk Stratification Models in Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma Myeloma & Leukemia 2023, 23: s359-s360. DOI: 10.1016/s2152-2650(23)01176-x.
- Aguirre L, Al Ali N, Sallman D, Kuykendall A, Chan O, Sweet K, Lancet J, Padron E, Komrokji R. POSTER: MDS-266 A Comprehensive Assessment of the Molecular International Prognostic Scoring System (IPSS-M) and Other Molecularly Integrated Risk Stratification Models in Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma Myeloma & Leukemia 2023, 23: s181. DOI: 10.1016/s2152-2650(23)00585-2.
- Aguirre L, Jain A, Ball S, Al Ali N, Sallman D, Kuykendall A, Chan O, Xie Z, Walker A, Sweet K, Lancet J, Padron E, Komrokji R. P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS‐M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS. HemaSphere 2023, 7: e6555734. PMCID: PMC10428761, DOI: 10.1097/01.hs9.0000969812.65557.34.
- Jain A, Ball S, Aguirre L, Tobon K, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman D, Lancet J, Sweet K. Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2023, 23: e315-e322. PMID: 37558530, DOI: 10.1016/j.clml.2023.07.002.
- Komrokji R, Aguirre L, Al-Ali N, Chan O, Xie Z, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Advances 2023, 7: 3677-3679. PMID: 37058483, PMCID: PMC10365940, DOI: 10.1182/bloodadvances.2023009781.
- Aguirre L, Jain A, Ball S, Al Ali N, Sallman D, Kuykendall A, Chan O, Xie Z, Walker A, Sweet K, Lancet J, Padron E, Komrokji R. Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models. Journal Of Clinical Oncology 2023, 41: 7020-7020. DOI: 10.1200/jco.2023.41.16_suppl.7020.
- Aguirre L, Al Ali N, Sallman D, Ball S, Jain A, Chan O, Tinsley-Vance S, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia 2023, 37: 1530-1539. PMID: 37147425, DOI: 10.1038/s41375-023-01910-3.
- Aguirre L, Sallman D, Stone R, Komrokji R. Updates in Risk Stratification in Myelodysplastic Syndromes. The Cancer Journal 2023, 29: 138-142. PMID: 37195769, DOI: 10.1097/ppo.0000000000000654.
- Tinsley-Vance S, Ali N, Ball S, Aguirre L, Jain A, Hussaini M, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes. Clinical Lymphoma Myeloma & Leukemia 2023, 23: 355-359. PMID: 36813626, PMCID: PMC10121764, DOI: 10.1016/j.clml.2023.01.007.
- Ball S, Aguirre L, Jain A, Ali N, Tinsley S, Chan O, Kuykendall A, Sweet K, Lancet J, Sallman D, Hussaini M, Padron E, Komrokji R. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. Leukemia Research 2022, 124: 106999. PMID: 36542963, DOI: 10.1016/j.leukres.2022.106999.
- Aguirre L, Al Ali N, Jain A, Chan O, Ball S, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R, Sallman D. Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes. Blood 2022, 140: 4034-4035. DOI: 10.1182/blood-2022-171093.
- Aguirre L, Al Ali N, Ball S, Singh A, Jain A, Chan O, Schwabkey Z, Tinsley-Vance S, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes. Blood 2022, 140: 6909-6911. DOI: 10.1182/blood-2022-171044.
- Aguirre L, Al Ali N, Ball S, Singh A, Jain A, Chan O, Schwabkey Z, Tinsley-Vance S, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes. Blood 2022, 140: 9813-9815. DOI: 10.1182/blood-2022-170980.
- Aguirre L, Al Ali N, Ball S, Singh A, Jain A, Chan O, Schwabkey Z, Tinsley-Vance S, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes. Blood 2022, 140: 1125-1127. DOI: 10.1182/blood-2022-170878.
- Jain A, Ball S, Aguirre L, Kuykendall A, Chan O, Komrokji R, Padron E, Sallman D, Lancet J, Mishra A, Sweet K. Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351. Blood 2022, 140: 1447-1449. DOI: 10.1182/blood-2022-170807.
- Ball S, Jain A, Patel P, Wang C, Aguirre L, Hussaini M, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet J, Komrokji R, Sallman D. Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia. Blood 2022, 140: 6282-6284. DOI: 10.1182/blood-2022-170442.
- Ball S, Singh A, Al Ali N, Aguirre L, Jain A, Schwabkey Z, Tinsley-Vance S, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome. Blood 2022, 140: 1118-1120. DOI: 10.1182/blood-2022-170158.
- Komrokji R, Aguirre L, Al Ali N, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D. Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes. Blood 2022, 140: 6917-6919. DOI: 10.1182/blood-2022-169560.
- Hunter A, Newman H, Solary E, Geissler K, Palomo L, Zamora L, Solé F, Santini V, Graubert T, Thota S, Griffiths E, Pleyer L, Thol F, Bejar R, Aguirre L, Sallman D, Kuykendall A, Komrokji R, George T, Padron E. Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features. Blood 2022, 140: 9824-9827. DOI: 10.1182/blood-2022-164816.
- Schwabkey Z, Azem A, Al Ali N, Ball S, Aguirre L, Jain A, Singh A, Tinsley-Vance S, Chan O, Lancet J, Sweet K, Kuykendall A, Padron E, Sallman D, Komrokji R. Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal. Blood 2022, 140: 6974-6975. DOI: 10.1182/blood-2022-156974.
- Aguirre L, Al Ali N, Sallman D, Jain A, Ball S, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. MDS-519 Outcome Predictors and Timing Considerations for Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s320. DOI: 10.1016/s2152-2650(22)01426-4.
- Jain A, Wang C, Ball S, Aguirre L, Schwabkey Z, Tobon K, Kuykendall A, Chan O, Padron E, Lancet J, Komrokji R, Sweet K, Sallman D. AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s258-s259. DOI: 10.1016/s2152-2650(22)01310-6.
- Ball S, Jain A, Patel P, Wang C, Aguirre L, Schwabkey Z, Hussaini M, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet J, Komrokji R, Sallman D. AML-488 Impact of Somatic Mutations on Treatment Response and Outcomes in Patients With Core Binding Factor Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s256. DOI: 10.1016/s2152-2650(22)01305-2.
- Aguirre L, Al Ali N, Sallman D, Jain A, Ball S, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Poster: MDS-519 Outcome Predictors and Timing Considerations for Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s154. DOI: 10.1016/s2152-2650(22)00944-2.
- Jain A, Wang C, Ball S, Aguirre L, Schwabkey Z, Tobon K, Kuykendall A, Chan O, Padron E, Lancet J, Komrokji R, Sweet K, Sallman D. Poster: AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s136. DOI: 10.1016/s2152-2650(22)00826-6.
- Ball S, Jain A, Patel P, Wang C, Aguirre L, Schwabkey Z, Hussaini M, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet J, Komrokji R, Sallman D. Poster: AML-488 Impact of Somatic Mutations on Treatment Response and Outcomes in Patients With Core Binding Factor Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s136. DOI: 10.1016/s2152-2650(22)00822-9.
- U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromesKomrokji R, Aguirre L, Al-Ali N, Hussaini M, Sallman D, Rollison D, Padron E. U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes. Blood Advances 2022, 7: 1-8. PMID: 36129843, PMCID: PMC9813529, DOI: 10.1182/bloodadvances.2022007504.
- Aguirre L, Ball S, Jain A, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML. HemaSphere 2022, 6: 650-651. DOI: 10.1097/01.hs9.0000845904.69112.ee.
- Aguirre L, Ball S, Jain A, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Hyperferritinemia as predictive biomarker of poor clinical outcomes in CMML. Journal Of Clinical Oncology 2022, 40: 7055-7055. DOI: 10.1200/jco.2022.40.16_suppl.7055.
- Ball S, Jain A, Aguirre L, Al Ali N, Zhang Y, Chan O, Kuykendall A, Sweet K, Lancet J, Swoboda D, Padron E, Komrokji R, Sallman D. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better? American Journal Of Hematology 2022, 97: e185-e188. PMID: 35179241, DOI: 10.1002/ajh.26504.
- Aguirre L, Yao J, Mesa T, Wloch M, Yoder S, Brass S, Cen L, Fontaine J, Pimiento J, Mehta R. Transcriptomic analyses of esophageal cancer patients with brain metastases. Journal Of Clinical Oncology 2022, 40: 341-341. DOI: 10.1200/jco.2022.40.4_suppl.341.
- Ball S, Jain A, Aguirre L, Al Ali N, Zhang Y, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Swoboda D, Komrokji R, Sallman D. Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia. Blood 2021, 138: 4138. DOI: 10.1182/blood-2021-153681.
- Ball S, Aguirre L, Jain A, Hussaini M, Al Ali N, Tinsley-Vance S, Chan O, Kuykendall A, Sweet K, Lancet J, Sallman D, Padron E, Komrokji R. Clinical Characteristics and Outcome of Patients with EZH2- Mutant Myelodysplastic Syndromes. Blood 2021, 138: 1531. DOI: 10.1182/blood-2021-153465.
- Aguirre L, Jain A, Ball S, Al Ali N, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Kuykendall A, Komrokji R. Clinico-Molecular Features and Treatment Outcomes in Primary Myelofibrosis Phenotypes with Protracted Disease Dynamics. Blood 2021, 138: 2571. DOI: 10.1182/blood-2021-152026.
- Aguirre L, Jain A, Ball S, Al Ali N, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Blood 2021, 138: 1494. DOI: 10.1182/blood-2021-151978.
- Tinsley-Vance S, Al Ali N, Ball S, Jain A, Aguirre L, Kaldas D, Chan O, Padron E, Sweet K, Lancet J, Kuykendall A, Sallman D, Komrokji R. A Focus on Phenotype and Genotype: Racial /Ethnic Disparities in Myelodysplastic Syndromes. Blood 2021, 138: 1985. DOI: 10.1182/blood-2021-151704.
- Tinsley-Vance S, Al Ali N, Ball S, Aguirre L, Jain A, Kaldas D, Chan O, Padron E, Sweet K, Lancet J, Kuykendall A, Sallman D, Komrokji R. Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes. Blood 2021, 138: 1984. DOI: 10.1182/blood-2021-149894.
- Jain A, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria. Blood 2021, 138: 2600. DOI: 10.1182/blood-2021-149708.
- Aguirre L, Ball S, Jain A, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Identification of Dynamic Disease Features of Progression and Need for Treatment. Blood 2021, 138: 1523. DOI: 10.1182/blood-2021-149283.
- Aguirre L, Komrokji R, Padron E. It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS. Best Practice & Research Clinical Haematology 2021, 34: 101325. PMID: 34865697, DOI: 10.1016/j.beha.2021.101325.
- Aguirre L, Ball S, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Poster: MDS-229: Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s227. DOI: 10.1016/s2152-2650(21)01433-6.
- Aguirre L, Ball S, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Oral Abstract: MDS-229: Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s201. DOI: 10.1016/s2152-2650(21)01269-6.
- Ball S, Jain A, Al Ali N, Hayden A, Swoboda D, Aguirre L, Sallman D, Padron E, Sweet K, Lancet J, Watts J, Pollyea D, Komrokji R. Poster: AML-225: Outcome with Intensive Chemotherapy vs Hypomethylating Agent-Based Induction Strategies in Patients Older Than 70 Years with Newly Diagnosed, Favorable-Risk Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s213. DOI: 10.1016/s2152-2650(21)01340-9.
- Ball S, Jain A, Al Ali N, Hayden A, Swoboda D, Aguirre L, Sallman D, Padron E, Sweet K, Lancet J, Watts J, Pollyea D, Komrokji R. AML-225: Outcome with Intensive Chemotherapy vs Hypomethylating Agent-Based Induction Strategies in Patients Older Than 70 Years with Newly Diagnosed, Favorable-Risk Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s293. DOI: 10.1016/s2152-2650(21)01700-6.
- Aguirre L, Ball S, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. MDS-229: Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s344-s345. DOI: 10.1016/s2152-2650(21)01801-2.
- Blanquicett C, Aguirre L. Therapeutic Advances for Pancreatic Cancer: a Slow and Challenging Feat that Continues to Evolve. Acta Scientific Gastrointestinal Disorders 2021, 4: 50-52. PMID: 34414366, PMCID: PMC8372192, DOI: 10.31080/asgis.2021.04.0268.
- Aguirre L, Fontaine J, Frakes J, Hoffe S, Pimiento J, Mehta R. HSR21-041: Impact of Cardiac Comorbidities on Outcomes After Treatment for Locally Advanced Esophageal Cancer: An Institutional Experience. Journal Of The National Comprehensive Cancer Network 2021, 19: hsr21-041. DOI: 10.6004/jnccn.2020.7756.
- Noor A, Aguirre L, Blue K, Avriett T, Carballido E, Kim R, Kim D. Investigate the efficacy of immunotherapy for treatment of pancreatic adenocarcinoma (PDAC) with mismatch repair deficiency (dMMR). Journal Of Clinical Oncology 2021, 39: 415-415. DOI: 10.1200/jco.2021.39.3_suppl.415.
- Aguirre L, Schwartz I, Chapman J, Larsen M, Alencar A. Adult Langerhans cell histiocytosis presenting with multisystem involvement and sarcomatoid features: a case report. Journal Of Medical Case Reports 2020, 14: 169. PMID: 32979930, PMCID: PMC7520028, DOI: 10.1186/s13256-020-02460-3.
- Aguirre L, Zamora Gonzalez R, Barreto-Coelho P, Yannuzzi N, Taldone S. Endogenous Endophthalmitis Heralding Central Nervous System Involvement by Nocardia Farcinica. Cureus 2020, 12: e9896. PMID: 32968562, PMCID: PMC7505538, DOI: 10.7759/cureus.9896.
- Husnain M, Komanduri K, Ramdial J, Lekakis L, Wang T, Goodman M, Pereira D, Beitinjaneh A, Carollo D, Ali R, Mohammed Y, Arshad J, Byrnes D, Saul E, Aguirre L, Jimenez A. Pre-transplant molecular minimal residual disease (MMRD) is associated with inferior outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Journal Of Clinical Oncology 2020, 38: 7547-7547. DOI: 10.1200/jco.2020.38.15_suppl.7547.
- Bradley T, Zuquello R, Aguirre L, Mackrides N, Chapman J, Cimmino L, Thomassen A, Watts J. Spontaneous remission of acute myeloid leukemia with NF1 alteration. Leukemia Research Reports 2020, 13: 100204. PMID: 32477862, PMCID: PMC7251391, DOI: 10.1016/j.lrr.2020.100204.
- Paul Y, Aguirre L, Basher F, Miao F, Koru-Sengul T, Hoffman J. Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience. Blood 2019, 134: 3131. DOI: 10.1182/blood-2019-127247.
- Ramdial J, Aguirre L, Ali R, Swords R, Goodman M. Aplasia in Chronic Phase CML Post‐TKI Therapy: A Management Dilemma. Case Reports In Hematology 2019, 2019: 4861673. PMID: 31662918, PMCID: PMC6778880, DOI: 10.1155/2019/4861673.
- Aguirre L, Salcedo J, Zuquello R, Garcia-Buitrago M, Ardalan B. Metastatic involvement of skeletal muscle from gastric adenocarcinoma. Oxford Medical Case Reports 2019, 2019: omz081. PMID: 31772748, PMCID: PMC6736074, DOI: 10.1093/omcr/omz081.
- Aguirre L, Ali R, Kerr D, Khanlari M, Lopes G. Kaposiform Hemangioendothelioma of the GI Tract: An Exception to Occam’s Principle in an Adult with SBO. Case Reports In Oncological Medicine 2019, 2019: 3269326. PMID: 31093393, PMCID: PMC6476061, DOI: 10.1155/2019/3269326.
- Aguirre L, Chueng T, Lorio M, Mueller M. Anchoring Bias, Lyme Disease, and the Diagnosis Conundrum. Cureus 2019, 11: e4300. PMID: 31183280, PMCID: PMC6538114, DOI: 10.7759/cureus.4300.
- Torres A, Ramdial J, Aguirre L, Mahtani R, Vogel C. Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients. Breast Cancer Research And Treatment 2019, 176: 253-260. PMID: 30900138, DOI: 10.1007/s10549-019-05203-1.
- Aguirre L, Guzman M, Lopes G, Hurley J. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue. The Oncologist 2018, 24: 394-401. PMID: 30413665, PMCID: PMC6519766, DOI: 10.1634/theoncologist.2018-0195.
- Erazo I, Galvis C, Aguirre L, Iglesias R, Abarca L, Abarca L. Clival Chondroid Chordoma: A Case Report and Review of the Literature. Cureus 2018, 10: e3381. PMID: 30519520, PMCID: PMC6263615, DOI: 10.7759/cureus.3381.
Departments and Programs
Locations
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Titles
- Assistant Professor of Medicine (Medical Oncology & Hematology)
Education & Training
- MPHHarvard T.H. Chan School of Public Health (2026)
- Foley Family Fellowship in LeukemiaDana-Farber Cancer Institute, Harvard Medical School (2025)
- Non Degree ProgramHarvard Medical School, Program in Clinical Effectiveness (2023)
- Medical OncologyH. Lee Moffitt Cancer Center and Research Institute (2023)
- HematologyH. Lee Moffitt Cancer Center and Research Institute (2023)
- Internal MedicineUniversity of Miami Miller School of Medicine (2020)
Languages Spoken
- English
- Deutsch (German)
- Español (Spanish)
Additional Information
Honors & Recognitions
- ASCO Conquer Cancer Merit Award: American Society of Clinical Oncology (2025)
- ASH Abstract Merit Award: American Society of Hematology (2024)
- New Investigator Travel Award: AA & MDS International Foundation (2024)
- ASCO Conquer Cancer Merit Award: American Society of Clinical Oncology (2023)
- ASH Clinical Research Training Institute: American Society of Hematology (2023)
- Foley Family Fellowship in Leukemia: Dana-Farber Cancer Institute, Harvard Medical School (2023), (2024)
- EHA Young Investigator Merit Award: European Hematology Association (2023)
- Featured Presenter, Moffitt Cancer Center 13th Annual Scientific Symposium: Moffitt Cancer Center (2023)
- Hematology/Oncology Fellow Liaison to the Florida Society of Clinical Oncology Board of Directors: Florida Society of Clinical Oncology (2023)
- ASH Abstract Merit Award: American Society of Hematology (2022)
Board Certifications
- AB of Internal Medicine, Hematology (Internal Medicine) (2023)
- AB of Internal Medicine, Medical Oncology (2023)
- AB of Internal Medicine, Internal Medicine (2020)
Professional Service
- American Society of Hematology (2024 - Present): Abstract Reviewer
- Harvard Ecuadorian Student Association (2024 - Present): Member
- Florida Society of Clinical Oncology (2023 - 2024): Liaison
- Massachusetts Society of Clinical Oncologists (2023 - Present): Member
- European Hematology Association (2022 - Present): Member
- European Society for Medical Oncology (2021 - 2023): Member
- Society of Hematologic Oncology (2021 - Present): Member
- American Association for Cancer Research (AACR) (2021 - Present): Member
- American Medical Association (2018 - 2023): Member
- American Society of Clinical Oncology (2018 - Present): Member
Publications
- Aguirre L, Al Ali N, Ball S, Jain A, Sallman D, Kuykendall A, Walker A, Sweet K, Lancet J, Padron E, Komrokji R. A comparative assessment of molecular-based prognostic models in CMML. Blood Neoplasia 2025, 2: 100116. DOI: 10.1016/j.bneo.2025.100116.
- Ball S, Jain A, Al Ali N, Aguirre L, Bewersdorf J, Kent A, Rose A, Hayden A, Siddon A, Lykon J, Madarang E, Swoboda D, Padron E, Sweet K, Sallman D, Lancet J, Carraway H, Watts J, Zeidan A, Pollyea D, Komrokji R. Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia. American Journal Of Hematology 2025, 100: 1920-1923. PMID: 40772639, DOI: 10.1002/ajh.70031.
- Aguirre L, Kim H, Elmariah H, Frumm S, Kelkar A, Ho V, Gooptu M, Antin J, Soiffer R, Shimony S, Luskin M, Garcia J, Chen E, Winer E, Stone R, DeAngelo D, Al Ali N, Cutler C, Komrokji R, Stahl M. Impact of static and dynamic risk assessment in HMA-treated MDS patients undergoing stem cell transplantation. Journal Of Clinical Oncology 2025, 43: 6568-6568. DOI: 10.1200/jco.2025.43.16_suppl.6568.
- Aguirre L, Ball S, Jain A, Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression. Clinical Lymphoma Myeloma & Leukemia 2025, 25: 661-671. PMID: 40254502, DOI: 10.1016/j.clml.2025.03.016.
- Consagra A, Lanino L, Al Ali N, Aguirre L, Xie Z, Chan O, Andreossi G, Raddi M, Rigodanza L, Sanna A, Mattiuz G, Tofacchi E, Amato C, Tanturli M, De Pourcq S, Walker A, Kuykendall A, Lancet J, Padron E, Sallman D, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Maggioni G, Campagna A, Della Porta M, Santini V, Komrokji R. Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS. HemaSphere 2025, 9: e70086. PMID: 39944234, PMCID: PMC11814532, DOI: 10.1002/hem3.70086.
- Ball S, Al Ali N, Jain A, Aguirre L, Yun S, Chan O, Xie Z, Sallman D, Lancet J, Padron E, Komrokji R, Kuykendall A. Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia. Frontiers In Hematology 2024, 3: 1492680. DOI: 10.3389/frhem.2024.1492680.
- Iat A, Bewersdorf J, Gilhodes J, Liu Y, Shallis R, Boussi L, Zucenka A, Bystrom R, DeAngelo D, Berton G, Soua A, Ling K, Aguirre L, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Goldberg A, Zeidan A, Cluzeau T, Shimony S, Stahl M, Garciaz S. Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia. Blood 2024, 144: 1508. DOI: 10.1182/blood-2024-207045.
- Bystrom R, Bewersdorf J, Liu Y, Schaefer E, Shallis R, Boussi L, Zucenka A, Garciaz S, Aguirre L, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study. Blood 2024, 144: 2947-2947. DOI: 10.1182/blood-2024-205581.
- Boussi L, Bewersdorf J, Liu Y, Shallis R, Aguirre L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Zeidan A, Goldberg A, Stein E, Shimony S, Stahl M. Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities. Blood 2024, 144: 4281-4281. DOI: 10.1182/blood-2024-204467.
- Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics. Blood 2024, 144: 4267-4267. DOI: 10.1182/blood-2024-202744.
- Zhang J, Shimony S, Liu Y, Inyang E, Chen E, Aguirre L, Bystrom R, Rolles B, Stone R, DeAngelo D, Tiao E, Stahl M. Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy. Blood 2024, 144: 5175-5175. DOI: 10.1182/blood-2024-200358.
- Aguirre L, Jain A, Ball S, Ali N, Volpe V, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clinical Lymphoma Myeloma & Leukemia 2024, 24: 459-467. PMID: 38548563, DOI: 10.1016/j.clml.2024.03.001.
- Jain A, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica 2024, 109: 2157-2164. PMID: 38299605, PMCID: PMC11215361, DOI: 10.3324/haematol.2023.283661.
- Consagra A, Lanino L, Al Ali N, Aguirre L, Xie Z, Chan O, Andreossi G, Rigodanza L, Sanna A, Raddi M, Walker A, Kuykendall A, Lancet J, Padron E, Sallman D, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Campagna A, Della Porta M, Santini V, Komrokji R. Improved Overall Survival Among Luspatercept Responders and Predictors of Response. Blood 2023, 142: 1871. DOI: 10.1182/blood-2023-186279.
- Chan O, Aguirre L, Burke M, Al Ali N, Xie Z, Yun S, Kuykendall A, Padron E, Walker A, Lancet J, Komrokji R, Sallman D. Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax. Blood 2023, 142: 5935. DOI: 10.1182/blood-2023-173637.
- Patel P, Ball S, Jain A, Wang C, Hussaini M, Aguirre L, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet J, Komrokji R, Sallman D. Drivers of deep molecular response and long‐term outcomes in patients with core binding factor acute myeloid leukemia. American Journal Of Hematology 2023, 98: e360-e363. PMID: 37705256, DOI: 10.1002/ajh.27092.
- Aguirre L, Al Ali N, Sallman D, Kuykendall A, Chan O, Sweet K, Lancet J, Padron E, Komrokji R. MDS-266 A Comprehensive Assessment of the Molecular International Prognostic Scoring System (IPSS-M) and Other Molecularly Integrated Risk Stratification Models in Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma Myeloma & Leukemia 2023, 23: s359-s360. DOI: 10.1016/s2152-2650(23)01176-x.
- Aguirre L, Al Ali N, Sallman D, Kuykendall A, Chan O, Sweet K, Lancet J, Padron E, Komrokji R. POSTER: MDS-266 A Comprehensive Assessment of the Molecular International Prognostic Scoring System (IPSS-M) and Other Molecularly Integrated Risk Stratification Models in Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma Myeloma & Leukemia 2023, 23: s181. DOI: 10.1016/s2152-2650(23)00585-2.
- Aguirre L, Jain A, Ball S, Al Ali N, Sallman D, Kuykendall A, Chan O, Xie Z, Walker A, Sweet K, Lancet J, Padron E, Komrokji R. P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS‐M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS. HemaSphere 2023, 7: e6555734. PMCID: PMC10428761, DOI: 10.1097/01.hs9.0000969812.65557.34.
- Jain A, Ball S, Aguirre L, Tobon K, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman D, Lancet J, Sweet K. Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2023, 23: e315-e322. PMID: 37558530, DOI: 10.1016/j.clml.2023.07.002.
- Komrokji R, Aguirre L, Al-Ali N, Chan O, Xie Z, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Advances 2023, 7: 3677-3679. PMID: 37058483, PMCID: PMC10365940, DOI: 10.1182/bloodadvances.2023009781.
- Aguirre L, Jain A, Ball S, Al Ali N, Sallman D, Kuykendall A, Chan O, Xie Z, Walker A, Sweet K, Lancet J, Padron E, Komrokji R. Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models. Journal Of Clinical Oncology 2023, 41: 7020-7020. DOI: 10.1200/jco.2023.41.16_suppl.7020.
- Aguirre L, Al Ali N, Sallman D, Ball S, Jain A, Chan O, Tinsley-Vance S, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia 2023, 37: 1530-1539. PMID: 37147425, DOI: 10.1038/s41375-023-01910-3.
- Aguirre L, Sallman D, Stone R, Komrokji R. Updates in Risk Stratification in Myelodysplastic Syndromes. The Cancer Journal 2023, 29: 138-142. PMID: 37195769, DOI: 10.1097/ppo.0000000000000654.
- Tinsley-Vance S, Ali N, Ball S, Aguirre L, Jain A, Hussaini M, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes. Clinical Lymphoma Myeloma & Leukemia 2023, 23: 355-359. PMID: 36813626, PMCID: PMC10121764, DOI: 10.1016/j.clml.2023.01.007.
- Ball S, Aguirre L, Jain A, Ali N, Tinsley S, Chan O, Kuykendall A, Sweet K, Lancet J, Sallman D, Hussaini M, Padron E, Komrokji R. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. Leukemia Research 2022, 124: 106999. PMID: 36542963, DOI: 10.1016/j.leukres.2022.106999.
- Aguirre L, Al Ali N, Jain A, Chan O, Ball S, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R, Sallman D. Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes. Blood 2022, 140: 4034-4035. DOI: 10.1182/blood-2022-171093.
- Aguirre L, Al Ali N, Ball S, Singh A, Jain A, Chan O, Schwabkey Z, Tinsley-Vance S, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes. Blood 2022, 140: 6909-6911. DOI: 10.1182/blood-2022-171044.
- Aguirre L, Al Ali N, Ball S, Singh A, Jain A, Chan O, Schwabkey Z, Tinsley-Vance S, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes. Blood 2022, 140: 9813-9815. DOI: 10.1182/blood-2022-170980.
- Aguirre L, Al Ali N, Ball S, Singh A, Jain A, Chan O, Schwabkey Z, Tinsley-Vance S, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes. Blood 2022, 140: 1125-1127. DOI: 10.1182/blood-2022-170878.
- Jain A, Ball S, Aguirre L, Kuykendall A, Chan O, Komrokji R, Padron E, Sallman D, Lancet J, Mishra A, Sweet K. Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351. Blood 2022, 140: 1447-1449. DOI: 10.1182/blood-2022-170807.
- Ball S, Jain A, Patel P, Wang C, Aguirre L, Hussaini M, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet J, Komrokji R, Sallman D. Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia. Blood 2022, 140: 6282-6284. DOI: 10.1182/blood-2022-170442.
- Ball S, Singh A, Al Ali N, Aguirre L, Jain A, Schwabkey Z, Tinsley-Vance S, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome. Blood 2022, 140: 1118-1120. DOI: 10.1182/blood-2022-170158.
- Komrokji R, Aguirre L, Al Ali N, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman D. Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes. Blood 2022, 140: 6917-6919. DOI: 10.1182/blood-2022-169560.
- Hunter A, Newman H, Solary E, Geissler K, Palomo L, Zamora L, Solé F, Santini V, Graubert T, Thota S, Griffiths E, Pleyer L, Thol F, Bejar R, Aguirre L, Sallman D, Kuykendall A, Komrokji R, George T, Padron E. Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features. Blood 2022, 140: 9824-9827. DOI: 10.1182/blood-2022-164816.
- Schwabkey Z, Azem A, Al Ali N, Ball S, Aguirre L, Jain A, Singh A, Tinsley-Vance S, Chan O, Lancet J, Sweet K, Kuykendall A, Padron E, Sallman D, Komrokji R. Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal. Blood 2022, 140: 6974-6975. DOI: 10.1182/blood-2022-156974.
- Aguirre L, Al Ali N, Sallman D, Jain A, Ball S, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. MDS-519 Outcome Predictors and Timing Considerations for Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s320. DOI: 10.1016/s2152-2650(22)01426-4.
- Jain A, Wang C, Ball S, Aguirre L, Schwabkey Z, Tobon K, Kuykendall A, Chan O, Padron E, Lancet J, Komrokji R, Sweet K, Sallman D. AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s258-s259. DOI: 10.1016/s2152-2650(22)01310-6.
- Ball S, Jain A, Patel P, Wang C, Aguirre L, Schwabkey Z, Hussaini M, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet J, Komrokji R, Sallman D. AML-488 Impact of Somatic Mutations on Treatment Response and Outcomes in Patients With Core Binding Factor Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s256. DOI: 10.1016/s2152-2650(22)01305-2.
- Aguirre L, Al Ali N, Sallman D, Jain A, Ball S, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Poster: MDS-519 Outcome Predictors and Timing Considerations for Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s154. DOI: 10.1016/s2152-2650(22)00944-2.
- Jain A, Wang C, Ball S, Aguirre L, Schwabkey Z, Tobon K, Kuykendall A, Chan O, Padron E, Lancet J, Komrokji R, Sweet K, Sallman D. Poster: AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s136. DOI: 10.1016/s2152-2650(22)00826-6.
- Ball S, Jain A, Patel P, Wang C, Aguirre L, Schwabkey Z, Hussaini M, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet J, Komrokji R, Sallman D. Poster: AML-488 Impact of Somatic Mutations on Treatment Response and Outcomes in Patients With Core Binding Factor Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s136. DOI: 10.1016/s2152-2650(22)00822-9.
- U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromesKomrokji R, Aguirre L, Al-Ali N, Hussaini M, Sallman D, Rollison D, Padron E. U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes. Blood Advances 2022, 7: 1-8. PMID: 36129843, PMCID: PMC9813529, DOI: 10.1182/bloodadvances.2022007504.
- Aguirre L, Ball S, Jain A, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML. HemaSphere 2022, 6: 650-651. DOI: 10.1097/01.hs9.0000845904.69112.ee.
- Aguirre L, Ball S, Jain A, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Hyperferritinemia as predictive biomarker of poor clinical outcomes in CMML. Journal Of Clinical Oncology 2022, 40: 7055-7055. DOI: 10.1200/jco.2022.40.16_suppl.7055.
- Ball S, Jain A, Aguirre L, Al Ali N, Zhang Y, Chan O, Kuykendall A, Sweet K, Lancet J, Swoboda D, Padron E, Komrokji R, Sallman D. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better? American Journal Of Hematology 2022, 97: e185-e188. PMID: 35179241, DOI: 10.1002/ajh.26504.
- Aguirre L, Yao J, Mesa T, Wloch M, Yoder S, Brass S, Cen L, Fontaine J, Pimiento J, Mehta R. Transcriptomic analyses of esophageal cancer patients with brain metastases. Journal Of Clinical Oncology 2022, 40: 341-341. DOI: 10.1200/jco.2022.40.4_suppl.341.
- Ball S, Jain A, Aguirre L, Al Ali N, Zhang Y, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Swoboda D, Komrokji R, Sallman D. Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia. Blood 2021, 138: 4138. DOI: 10.1182/blood-2021-153681.
- Ball S, Aguirre L, Jain A, Hussaini M, Al Ali N, Tinsley-Vance S, Chan O, Kuykendall A, Sweet K, Lancet J, Sallman D, Padron E, Komrokji R. Clinical Characteristics and Outcome of Patients with EZH2- Mutant Myelodysplastic Syndromes. Blood 2021, 138: 1531. DOI: 10.1182/blood-2021-153465.
- Aguirre L, Jain A, Ball S, Al Ali N, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Kuykendall A, Komrokji R. Clinico-Molecular Features and Treatment Outcomes in Primary Myelofibrosis Phenotypes with Protracted Disease Dynamics. Blood 2021, 138: 2571. DOI: 10.1182/blood-2021-152026.
- Aguirre L, Jain A, Ball S, Al Ali N, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Blood 2021, 138: 1494. DOI: 10.1182/blood-2021-151978.
- Tinsley-Vance S, Al Ali N, Ball S, Jain A, Aguirre L, Kaldas D, Chan O, Padron E, Sweet K, Lancet J, Kuykendall A, Sallman D, Komrokji R. A Focus on Phenotype and Genotype: Racial /Ethnic Disparities in Myelodysplastic Syndromes. Blood 2021, 138: 1985. DOI: 10.1182/blood-2021-151704.
- Tinsley-Vance S, Al Ali N, Ball S, Aguirre L, Jain A, Kaldas D, Chan O, Padron E, Sweet K, Lancet J, Kuykendall A, Sallman D, Komrokji R. Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes. Blood 2021, 138: 1984. DOI: 10.1182/blood-2021-149894.
- Jain A, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria. Blood 2021, 138: 2600. DOI: 10.1182/blood-2021-149708.
- Aguirre L, Ball S, Jain A, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Identification of Dynamic Disease Features of Progression and Need for Treatment. Blood 2021, 138: 1523. DOI: 10.1182/blood-2021-149283.
- Aguirre L, Komrokji R, Padron E. It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS. Best Practice & Research Clinical Haematology 2021, 34: 101325. PMID: 34865697, DOI: 10.1016/j.beha.2021.101325.
- Aguirre L, Ball S, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Poster: MDS-229: Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s227. DOI: 10.1016/s2152-2650(21)01433-6.
- Aguirre L, Ball S, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. Oral Abstract: MDS-229: Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s201. DOI: 10.1016/s2152-2650(21)01269-6.
- Ball S, Jain A, Al Ali N, Hayden A, Swoboda D, Aguirre L, Sallman D, Padron E, Sweet K, Lancet J, Watts J, Pollyea D, Komrokji R. Poster: AML-225: Outcome with Intensive Chemotherapy vs Hypomethylating Agent-Based Induction Strategies in Patients Older Than 70 Years with Newly Diagnosed, Favorable-Risk Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s213. DOI: 10.1016/s2152-2650(21)01340-9.
- Ball S, Jain A, Al Ali N, Hayden A, Swoboda D, Aguirre L, Sallman D, Padron E, Sweet K, Lancet J, Watts J, Pollyea D, Komrokji R. AML-225: Outcome with Intensive Chemotherapy vs Hypomethylating Agent-Based Induction Strategies in Patients Older Than 70 Years with Newly Diagnosed, Favorable-Risk Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s293. DOI: 10.1016/s2152-2650(21)01700-6.
- Aguirre L, Ball S, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet J, Padron E, Komrokji R. MDS-229: Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s344-s345. DOI: 10.1016/s2152-2650(21)01801-2.
- Blanquicett C, Aguirre L. Therapeutic Advances for Pancreatic Cancer: a Slow and Challenging Feat that Continues to Evolve. Acta Scientific Gastrointestinal Disorders 2021, 4: 50-52. PMID: 34414366, PMCID: PMC8372192, DOI: 10.31080/asgis.2021.04.0268.
- Aguirre L, Fontaine J, Frakes J, Hoffe S, Pimiento J, Mehta R. HSR21-041: Impact of Cardiac Comorbidities on Outcomes After Treatment for Locally Advanced Esophageal Cancer: An Institutional Experience. Journal Of The National Comprehensive Cancer Network 2021, 19: hsr21-041. DOI: 10.6004/jnccn.2020.7756.
- Noor A, Aguirre L, Blue K, Avriett T, Carballido E, Kim R, Kim D. Investigate the efficacy of immunotherapy for treatment of pancreatic adenocarcinoma (PDAC) with mismatch repair deficiency (dMMR). Journal Of Clinical Oncology 2021, 39: 415-415. DOI: 10.1200/jco.2021.39.3_suppl.415.
- Aguirre L, Schwartz I, Chapman J, Larsen M, Alencar A. Adult Langerhans cell histiocytosis presenting with multisystem involvement and sarcomatoid features: a case report. Journal Of Medical Case Reports 2020, 14: 169. PMID: 32979930, PMCID: PMC7520028, DOI: 10.1186/s13256-020-02460-3.
- Aguirre L, Zamora Gonzalez R, Barreto-Coelho P, Yannuzzi N, Taldone S. Endogenous Endophthalmitis Heralding Central Nervous System Involvement by Nocardia Farcinica. Cureus 2020, 12: e9896. PMID: 32968562, PMCID: PMC7505538, DOI: 10.7759/cureus.9896.
- Husnain M, Komanduri K, Ramdial J, Lekakis L, Wang T, Goodman M, Pereira D, Beitinjaneh A, Carollo D, Ali R, Mohammed Y, Arshad J, Byrnes D, Saul E, Aguirre L, Jimenez A. Pre-transplant molecular minimal residual disease (MMRD) is associated with inferior outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Journal Of Clinical Oncology 2020, 38: 7547-7547. DOI: 10.1200/jco.2020.38.15_suppl.7547.
- Bradley T, Zuquello R, Aguirre L, Mackrides N, Chapman J, Cimmino L, Thomassen A, Watts J. Spontaneous remission of acute myeloid leukemia with NF1 alteration. Leukemia Research Reports 2020, 13: 100204. PMID: 32477862, PMCID: PMC7251391, DOI: 10.1016/j.lrr.2020.100204.
- Paul Y, Aguirre L, Basher F, Miao F, Koru-Sengul T, Hoffman J. Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience. Blood 2019, 134: 3131. DOI: 10.1182/blood-2019-127247.
- Ramdial J, Aguirre L, Ali R, Swords R, Goodman M. Aplasia in Chronic Phase CML Post‐TKI Therapy: A Management Dilemma. Case Reports In Hematology 2019, 2019: 4861673. PMID: 31662918, PMCID: PMC6778880, DOI: 10.1155/2019/4861673.
- Aguirre L, Salcedo J, Zuquello R, Garcia-Buitrago M, Ardalan B. Metastatic involvement of skeletal muscle from gastric adenocarcinoma. Oxford Medical Case Reports 2019, 2019: omz081. PMID: 31772748, PMCID: PMC6736074, DOI: 10.1093/omcr/omz081.
- Aguirre L, Ali R, Kerr D, Khanlari M, Lopes G. Kaposiform Hemangioendothelioma of the GI Tract: An Exception to Occam’s Principle in an Adult with SBO. Case Reports In Oncological Medicine 2019, 2019: 3269326. PMID: 31093393, PMCID: PMC6476061, DOI: 10.1155/2019/3269326.
- Aguirre L, Chueng T, Lorio M, Mueller M. Anchoring Bias, Lyme Disease, and the Diagnosis Conundrum. Cureus 2019, 11: e4300. PMID: 31183280, PMCID: PMC6538114, DOI: 10.7759/cureus.4300.
- Torres A, Ramdial J, Aguirre L, Mahtani R, Vogel C. Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients. Breast Cancer Research And Treatment 2019, 176: 253-260. PMID: 30900138, DOI: 10.1007/s10549-019-05203-1.
- Aguirre L, Guzman M, Lopes G, Hurley J. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue. The Oncologist 2018, 24: 394-401. PMID: 30413665, PMCID: PMC6519766, DOI: 10.1634/theoncologist.2018-0195.
- Erazo I, Galvis C, Aguirre L, Iglesias R, Abarca L, Abarca L. Clival Chondroid Chordoma: A Case Report and Review of the Literature. Cureus 2018, 10: e3381. PMID: 30519520, PMCID: PMC6263615, DOI: 10.7759/cureus.3381.
Departments and Programs
Locations
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511